RXRA and cancer: Compound 7i displayed the most significant inhibitory activity, while its inhibitory activity dramatically decreased in RXRα-knockout MDA-MB-231 cell lines, suggesting that the anti-cancer activities of 7i against MDA-MB-231 cells acts in an RXRα-dependent manner.